MX2025000053A - Anticuerpos monoclonales anti-slc34a2 y sus usos - Google Patents

Anticuerpos monoclonales anti-slc34a2 y sus usos

Info

Publication number
MX2025000053A
MX2025000053A MX2025000053A MX2025000053A MX2025000053A MX 2025000053 A MX2025000053 A MX 2025000053A MX 2025000053 A MX2025000053 A MX 2025000053A MX 2025000053 A MX2025000053 A MX 2025000053A MX 2025000053 A MX2025000053 A MX 2025000053A
Authority
MX
Mexico
Prior art keywords
slc34a2
monoclonal antibodies
antibodies
binding
adcc
Prior art date
Application number
MX2025000053A
Other languages
English (en)
Spanish (es)
Inventor
Runsheng Li
Wentao Huang
Yifan Li
Original Assignee
Lanova Medicines Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lanova Medicines Dev Co Ltd filed Critical Lanova Medicines Dev Co Ltd
Publication of MX2025000053A publication Critical patent/MX2025000053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2025000053A 2022-06-22 2025-01-06 Anticuerpos monoclonales anti-slc34a2 y sus usos MX2025000053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2025000053A true MX2025000053A (es) 2025-04-02

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025000053A MX2025000053A (es) 2022-06-22 2025-01-06 Anticuerpos monoclonales anti-slc34a2 y sus usos

Country Status (14)

Country Link
US (2) US12215150B2 (cg-RX-API-DMAC10.html)
EP (1) EP4543926A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025520692A (cg-RX-API-DMAC10.html)
KR (1) KR20250051643A (cg-RX-API-DMAC10.html)
CN (1) CN119948054A (cg-RX-API-DMAC10.html)
AU (1) AU2023289743A1 (cg-RX-API-DMAC10.html)
CA (1) CA3260354A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024004012A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024017740A2 (cg-RX-API-DMAC10.html)
IL (1) IL317849A (cg-RX-API-DMAC10.html)
MX (1) MX2025000053A (cg-RX-API-DMAC10.html)
PE (1) PE20252048A1 (cg-RX-API-DMAC10.html)
TW (1) TW202409076A (cg-RX-API-DMAC10.html)
WO (1) WO2023246879A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024408814A1 (en) * 2023-12-21 2026-07-09 LaNova Medicines Limited Conjugates of anti-slc34a2 antibody and uses thereof
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
US20250154248A1 (en) 2025-05-15
CA3260354A1 (en) 2023-12-28
EP4543926A1 (en) 2025-04-30
CN119948054A (zh) 2025-05-06
JP2025520692A (ja) 2025-07-03
IL317849A (en) 2025-02-01
US12215150B2 (en) 2025-02-04
CO2024017740A2 (es) 2025-05-19
KR20250051643A (ko) 2025-04-17
US20240301052A1 (en) 2024-09-12
TW202409076A (zh) 2024-03-01
WO2023246879A1 (en) 2023-12-28
CL2024004012A1 (es) 2025-05-02
PE20252048A1 (es) 2025-08-21
AU2023289743A1 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
ZA202305221B (en) Tumor-specific claudin 18.2 antibody-drug conjugates
SA523442921B1 (ar) جزيئات ربط علاجية
MX2022013944A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
MX337052B (es) Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
NZ797493A (en) Anti-fgfr2 antibodies and methods of use thereof
UA114879C2 (uk) Антитіло до cd38 для лікування раку
MY154009A (en) Anti-alpha v beta 6 antibodies
ATE461220T1 (de) Anti-egfr-antikörper
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
MX2022010161A (es) Proteínas biespecíficas anti-her2 diseñadas.
CL2024004012A1 (es) Anticuerpos monoclonales anti-slc34a2 y sus usos
MX2025014033A (es) Anticuerpos y sus conjugados de anticuerpo y farmaco
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
CR20240462A (es) Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos
MX2024013676A (es) Anticuerpos triespecificos para cumulo de diferenciacion 3 (cd3)/antigeno de maduracion de celulas b (bcma)/cumulo de diferenciacion (cd38)
Chiang et al. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
PH12023552669A1 (en) Anti-clec12a antibodies and uses thereof
PH12023550745A1 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX2026000793A (es) Anticuerpo muc1 humanizado y conjugado anticuerpo-farmaco
MX2024009996A (es) Anticuerpos monoclonales anti-il-13ra2 y usos de los mismos
GB9906380D0 (en) Monoclonal antibodies specific for cypibi